Jamjoom Pharmaceuticals Factory Company SJSC (4015) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Jamjoom Pharmaceuticals Factory Company SJSC stock SAR 140, price SAR 122, upside +14.7%, quality 77 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value 30%+ above price?No
Quality 50+?Yes
In an uptrend?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
40‑month range 71.88 SAR – 191.96 SAR · fair‑value band 75.71 SAR – 209.85 SAR · the 122.00 SAR price screens below the 139.98 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow Jamjoom Pharmaceuticals Factory Company SJSC in your weekly email
Every Wednesday you see whether Jamjoom Pharmaceuticals Factory Company SJSC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally.
Show moreShow less
It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceuticals.
The company also offers ophthalmic solutions, dermatology products, cardiovascular health, consumer health, respiratory health, gastrointestinal health, endocrinology and diabetes care, central nervous system, and pain and inflammation pharmaceutical products.
Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdom of Saudi Arabia.
Stock analysis
Jamjoom Pharmaceuticals Factory Company SJSC (4015) currently trades at 122.00 SAR, while our model-based Fair Value estimate is 139.98 SAR, implying the stock looks roughly 12.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 161.43 SAR per share, and 10 of the 26 models we run sit above the 122.00 SAR price.
Bear case: the Economic Profit group reads lowest at 54.49 SAR, and 16 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 75.71 SAR (bear) to 209.85 SAR (bull), the price of 122.00 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Jamjoom Pharmaceuticals Factory Company SJSC reported revenue of 1.5B SAR in FY2025 versus 736M SAR in FY2021, a compound +19.5%/yr. Reported net income was 464M SAR in FY2025, compounding +28.4%/yr from FY2021.
Key figures
Market cap 8.6B SAR (≈ $2.3B) Mid · P/E ratio 17.8 · P/S ratio 5.45 · EPS (TTM) 6.87 SAR · Dividend yield 3.4% · Net margin 30.5% · Return on equity 27.0% · Return on assets (EBIT) 18.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 86 out of 100 (medium confidence).
What moves the price
The share trades about 24% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at 15%, 4015 screens cheaper than that median.
Fair Value models
Bear75.71 SARFair Value 139.98 SARBull209.85 SAR
Price 122.00 SAR · Upside +14.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.21 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.99/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+29.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.7%
Dividend (yield on the price)3.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 32%
2025 sits 58% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (Saudi Arabia: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +9.5% a year for the price and +7.6% for the forecasts.
Compare Jamjoom Pharmaceuticals Factory Company SJSC with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 579 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside+14.7% · Above median
Profitability
Return on equity (12 months)27.0% · Top 25%
Return on assets22.7% · Top 25%
Net margin (12 months)30.5% · Top 25%
Operating margin (12 months)32.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)12.4% · Above median
Dividend yield (12 months)3.4% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jamjoom Pharmaceuticals Factory Company SJSC Fair Value". https://www.fairvalue-calculator.com/stock/4015
Frequently asked questions
Is Jamjoom Pharmaceuticals Factory Company SJSC (4015) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of 139.98 SAR versus a price of 122.00 SAR, about +15% upside (undervalued).
What is the fair value of 4015?
Our model-based fair value for Jamjoom Pharmaceuticals Factory Company SJSC is 139.98 SAR (as of Oct 27, 2026), built from audited fundamentals. The current price: 122.00 SAR.
What is the quality score of 4015?
Jamjoom Pharmaceuticals Factory Company SJSC has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Our model-based price target is the fair value of 139.98 SAR (as of Oct 27, 2026) from 26 valuation models. Cautious scenario 75.71 SAR, optimistic scenario 209.85 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Jamjoom Pharmaceuticals Factory Company SJSC stock forecast for 2026?
Our models put fair value at 139.98 SAR, about +15% upside versus a price of 122.00 SAR (undervalued). Cautious scenario 75.71 SAR, optimistic scenario 209.85 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Jamjoom Pharmaceuticals Factory Company SJSC reported trailing-twelve-month revenue of about 1.6B SAR (latest available figure, as of Oct 27, 2026).
Does Jamjoom Pharmaceuticals Factory Company SJSC pay a dividend?
Jamjoom Pharmaceuticals Factory Company SJSC currently shows a dividend yield of 3.44% relative to its recent price (as of Oct 27, 2026).
What growth is priced into Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
For today's price to be fair in a discounted-cash-flow model, Jamjoom Pharmaceuticals Factory Company SJSC would have to grow free cash flow by +11.7 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.3 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of 4015 use?
Our models discount Jamjoom Pharmaceuticals Factory Company SJSC at 9.0 %: a base by market capitalisation (mid), damped by beta 0.36, country premium for Saudi Arabia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jamjoom Pharmaceuticals Factory Company SJSC that is +11.7 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Jamjoom Pharmaceuticals Factory Company SJSC (4015) delivered so far?
Over the past 5 years revenue at Jamjoom Pharmaceuticals Factory Company SJSC grew +13.3 % a year. The price currently implies +11.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jamjoom Pharmaceuticals Factory Company SJSC (4015) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Jamjoom Pharmaceuticals Factory Company SJSC (+11.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The free-cash-flow yield on the price is 3.87 %: that much free cash flow Jamjoom Pharmaceuticals Factory Company SJSC produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jamjoom Pharmaceuticals Factory Company SJSC it is 139.98 SAR per share (as of Oct 27, 2026), against a price of 122.00 SAR. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Jamjoom Pharmaceuticals Factory Company SJSC stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 4015 trades below its calculated fair value: price 122.00 SAR, fair value 139.98 SAR, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4015?
No. The price is what the market pays today (122.00 SAR); the fair value is what the company's own numbers justify (139.98 SAR). For Jamjoom Pharmaceuticals Factory Company SJSC the two are 17.98 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Jamjoom Pharmaceuticals Factory Company SJSC worth?
The market values Jamjoom Pharmaceuticals Factory Company SJSC at about 8.6B SAR (market capitalisation, as of Oct 27, 2026). Per share that is 122.00 SAR; our models calculate a fair value of 139.98 SAR per share.
What do the bullish and bearish scenarios say about 4015?
Our models span a range for Jamjoom Pharmaceuticals Factory Company SJSC: cautious scenario 75.71 SAR, base 139.98 SAR, optimistic 209.85 SAR per share (as of Oct 27, 2026, price 122.00 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4015?
Jamjoom Pharmaceuticals Factory Company SJSC trades at a price-to-earnings ratio of 17.8 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 139.98 SAR is built from several models across several years. Other multiples: P/B 5.0, P/S 5.4, EV/EBITDA 15.1.
How solid is the balance sheet of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Balance-sheet figures for Jamjoom Pharmaceuticals Factory Company SJSC (as of Oct 27, 2026): return on equity 27.0%. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is 4015 from its 52-week high?
Jamjoom Pharmaceuticals Factory Company SJSC trades at 122.00 SAR, about 24% below its 52-week high of 160.97 SAR and 3% above the low of 118.90 SAR (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 139.98 SAR is for.
Which stocks are comparable to Jamjoom Pharmaceuticals Factory Company SJSC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jamjoom Pharmaceuticals Factory Company SJSC stock attractive at the current price?
The data as of Oct 27, 2026: price 122.00 SAR, calculated fair value 139.98 SAR (+15%), Quality Score 77/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4015 calculated?
We run Jamjoom Pharmaceuticals Factory Company SJSC through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 139.98 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Jamjoom Pharmaceuticals Factory Company SJSC currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The closing price on Oct 28, 2026 was 122.00 SAR. Our model-based fair value is 139.98 SAR, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jamjoom Pharmaceuticals Factory Company SJSC right now?
The model range is unusually wide (75.71 SAR to 209.85 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Jamjoom Pharmaceuticals Factory Company SJSC
How large is the market capitalisation of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The market capitalisation of Jamjoom Pharmaceuticals Factory Company SJSC is 8.6B SAR (≈ $2.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The price-to-sales ratio of Jamjoom Pharmaceuticals Factory Company SJSC is 5.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Earnings per share at Jamjoom Pharmaceuticals Factory Company SJSC are 6.87 SAR (price ÷ EPS = P/E 17.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The dividend yield of Jamjoom Pharmaceuticals Factory Company SJSC is 3.4% (payout 61.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The net margin of Jamjoom Pharmaceuticals Factory Company SJSC is 30.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The return on equity (ROE) of Jamjoom Pharmaceuticals Factory Company SJSC is 27.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
On an EBIT basis the return on assets of Jamjoom Pharmaceuticals Factory Company SJSC is 18.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
The operating margin of Jamjoom Pharmaceuticals Factory Company SJSC is 32.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Revenue at Jamjoom Pharmaceuticals Factory Company SJSC is growing +12.4% versus a year earlier (3y avg +17.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jamjoom Pharmaceuticals Factory Company SJSC (4015)?
Earnings per share at Jamjoom Pharmaceuticals Factory Company SJSC are growing +4.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Jamjoom Pharmaceuticals Factory Company SJSC (4015) hold?
Jamjoom Pharmaceuticals Factory Company SJSC holds more cash than debt, 260M SAR net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Jamjoom Pharmaceuticals Factory Company SJSC in the live analysis
One click puts Jamjoom Pharmaceuticals Factory Company SJSC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 27, 2026